North & North · Research
Peptide Human Trials
Checked one by one against the registry
Thymosin Beta 4, the same peptide sold here as TB-500, has completed 3 placebo controlled late stage trials, 2 of them Phase 3, which enrolled 1,618 people between them. Another is recruiting. Across 11 records the registry counts 1,878 people actually enrolled, and in 2026 the FDA removed four of these compounds from its restricted compounding list.
Regulatory
What Changed In 2026
The compounds on this page spent 2026 moving in one direction. In April the FDA removed BPC-157, TB-500, MOTS-c and CJC-1295 from its restricted compounding list. BPC-157, TB-500 and MOTS-c then went to a public advisory committee in July, and the committee voted in favour of every one. Every step below links to the record it came from.
None of this makes a peptide an approved medicine, and none of it changes what North & North sells, which is research material. What changed in 2026 is that these compounds are being weighed on the public record by the agency that regulates them.
- The restricted listing came offApril 2026
The FDA removed twelve peptides from the list it keeps for substances it considers to present significant safety risks in compounding. BPC-157, TB-500, MOTS-c and CJC-1295 were all among them. The FDA list now files each of them as withdrawn.
- The FDA put it to a public reviewApril 2026
A Federal Register notice set two days of public advisory committee review for seven of those peptides and opened a docket, FDA-2025-N-6895, for anyone to file evidence or comment. Robert F. Kennedy Jr., Secretary of Health and Human Services, welcomed the move as long overdue and said it restored science and the rule of law.
- GHK-Cu sits in FDA Category 1May 2026
The FDA list files GHK-Cu under Category 1, which it titles Bulk Drug Substances Under Evaluation. For that category the agency states it does not intend to take action against a compounder, provided the conditions in its guidance are met. The FDA entry is qualified, and the exact wording is on the list linked below. The FDA has said it intends to consult the same advisory committee about GHK-Cu before the end of February 2027.
- The advisory committee backed themJuly 2026
Over two days the FDA Pharmacy Compounding Advisory Committee reviewed seven peptides and voted in favour of six. From this catalog, BPC-157, TB-500 and MOTS-c were reviewed, and every one of them came out with a favourable vote. The recommendation is that they be added to the list of bulk substances pharmacies are permitted to compound with.
Every step above was checked against its source in September 2026. The FDA sets the compounding list by rulemaking, so its own pages are the authority on where this stands next.
The register
The Register
Listed by compound, with status exactly as the registry states it, including the one that was terminated. None of these trials uses North & North material, and none is run by North & North.
Most of the register is Thymosin Beta 4, which is the same peptide sold here as TB-500, at the same full length. What differs is how each trial made it: the eye programme used a formulation called RGN-259, and the cardiac work used a recombinant version. Same peptide, different preparation, so it carries across with that in mind rather than not at all.
A note on three of them. The CJC-1295 record used the long acting DAC form rather than the No DAC form sold here, which is a different molecule, so it is not attached to a product page. GHK-Cu and MOTS-c have no registered trial of their own, and their 2026 record is the regulatory one above: GHK-Cu listed in FDA Category 1, and MOTS-c carried by the committee vote in July.
Scope: the research peptides in this catalog, BPC-157, GHK-Cu, MOTS-c, TB-500 and CJC-1295. Tirzepatide and Retatrutide are deliberately not here. They are also sold on this site, but they carry hundreds of registered trials between them and are mainstream pharmaceutical subjects, so listing a handful would misrepresent the field rather than describe it.
Registered trials are also not the whole record. CJC-1295 has three published human studies, including a randomised controlled trial in the Journal of Clinical Endocrinology and Metabolism, and BPC-157 has two published pilot studies in small groups of patients. Those are papers rather than registry records, so they are cited on the compound pages rather than listed here.
- PCO-02 (Bepecin), active ingredient BPC-157Unknown
Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157
PharmaCotherapia d.o.o.Phase 142 participants plannedStarted October 2015Placebo controlledThe only registered trial of BPC-157 itself. Its record was last updated in December 2015 and the registry still lists its status as unknown, with no results posted there.
- RGN-259, a Thymosin Beta 4 formulationCompleted
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLCPhase 3700 participantsStarted May 2019Placebo controlledThe largest trial of this peptide in people. Phase 3, placebo controlled, 700 participants, completed.
- RGN-259, a Thymosin Beta 4 formulationCompleted
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2
ReGenTree, LLCPhase 3601 participantsStarted November 2016Placebo controlledThe largest completed Phase 3 trial in this programme after ARISE-3. The programme ran three trials in total, of which this and ARISE-3 are registered Phase 3 and ARISE-1 is registered Phase 2 and 3.
- RGN-259, a Thymosin Beta 4 formulationCompleted
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
ReGenTree, LLCPhase 2 and 3317 participantsStarted September 2015Placebo controlledThe first of the three, and the trial the programme was built on.
- RGN-259, a Thymosin Beta 4 formulationRecruiting
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
ReGenTree, LLCPhase 370 participants plannedStarted April 2023Placebo controlledRecruiting now, in neurotrophic keratopathy. The one trial on this page a reader could still join.
- Thymosin Beta 4Completed
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
RegeneRx Biopharmaceuticals, Inc.Phase 272 participantsStarted May 2006Placebo controlledOne of the earliest controlled trials of this peptide in people, completed in wound repair.
- Thymosin Beta 4Completed
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
RegeneRx Biopharmaceuticals, Inc.Phase 272 participantsStarted July 2006Placebo controlledA second controlled wound repair trial from the same programme, also completed.
- Recombinant Human Thymosin Beta 4Completed
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Beijing Northland BiotechPhase 262 participantsStarted November 2020Placebo controlledCompleted cardiac trial. A recombinant preparation, which is made differently from the synthetic peptide sold here.
- Recombinant Human Thymosin Beta 4Completed
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
Beijing Northland BiotechPhase 154 participantsStarted July 2017Placebo controlledThe safety groundwork: a completed placebo controlled study in 54 healthy volunteers.
- Recombinant Human Thymosin Beta 4 (NL005)Not yet recruiting
Recombinant Human Thymosin Beta 4 for Acute Myocardial Infarction
Beijing Northland BiotechPhase 2189 participants plannedStarted May 2026Placebo controlledA different preparation of the same parent protein, listed because it is the largest of these and is often confused for a TB-500 trial.
- CJC-1295 (DAC form)Terminated
A Study to Evaluate CJC-1295 in Patients With Visceral Obesity
ConjuChemPhase 2120 participants recordedStarted December 2005The only CJC-1295 trial ever registered, and it was terminated. The registry records 120 people and states no enrolment type. It used the long acting DAC form rather than the No DAC form sold here, so it says nothing about that one either way.
Every record above was checked directly against ClinicalTrials.gov by its identifier on September 2026. Statuses change, so the registry is always the authority. If you find one of these out of date, the link beside it goes straight to the source.
Common questions
Questions People Ask
Is North & North material used in these trials?
No. Every trial listed here is run by its own sponsor using its own material, and North & North has no involvement in any of them. Most of them study Thymosin Beta 4, which is the same peptide sold here as TB-500 and at the same full length, but each used its own preparation: a formulation called RGN-259 in the eye programme, and a recombinant version in the cardiac work. The CJC-1295 record used the long acting DAC form rather than the No DAC form sold here, which is a different molecule, so it is not attached to a product page.
What did the FDA change in 2026?
In April 2026 the FDA removed twelve peptides from the list it keeps for substances it considers to present significant safety risks in compounding, and BPC-157, TB-500, MOTS-c and CJC-1295 were all among them. It referred seven peptides to its Pharmacy Compounding Advisory Committee, which met on 23 and 24 July 2026 and voted in favour of six. BPC-157, TB-500 and MOTS-c were the three from this catalog that were reviewed, and every one of them was among the six. GHK-Cu is listed under Category 1, which the FDA titles Bulk Drug Substances Under Evaluation, and the agency has said it intends to consult the same committee about GHK-Cu before the end of February 2027. Every step is dated and linked to its source higher up this page.
Where does the FDA process go next?
To the agency. A committee recommendation is advice, and the FDA sets the compounding list by rulemaking, so the next move is the FDA’s and its own pages are where to watch for it. To be exact about the status in the meantime: none of these peptides is an approved medicine, and none of this changes what North & North supplies, which is research material.
Did you remove trials from this page?
Yes. Four were removed on 2 September 2026, all sponsored by Hudson Biotech. One of them we had published as a real recruiting TB-500 trial, NCT07487363, and its own registry summary opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Of that sponsor’s seven registrations, a second is titled "(Mock Study)", a third describes itself as an example record, and a fourth is filed under SURMOUNT-1, the name of a real Eli Lilly trial. The remaining three we carried, for BPC-157, GHK-Cu and MOTS-c, contain no such wording, but they came from the same batch, so they went too. Check NCT07487363 against the registry yourself; that is the point of listing identifiers.
Have any of these reported results?
None has posted results to its registry record. The 2015 PharmaCotherapia study has not been updated since December of that year, so the registry does not say what became of it. Published papers are a separate record, and the ones that exist are cited on the compound pages.
Why is a terminated trial on the list?
Because leaving it out would make this an advert. The only CJC-1295 trial ever registered was terminated in 2005, and it studied the long acting DAC form rather than the No DAC form sold here. So the honest answer for No DAC is that no registered trial has ever studied it.
How current is this page?
Every record here was checked directly against the ClinicalTrials.gov registry by its identifier, and the date it was last checked is shown at the foot of the list. Statuses change, so the registry itself is always the authority.
Go deeper
Research on Each Compound
Catalog access
Create a Free Account
Create a quick and easy free account to shop every compound in the library and other peptides.
Free to create. You will verify your email address before the catalog opens.